VEGFA and neoplasm: Also, this study compared the effect of RhoJ-AuNPs with bevacizumab monoclonal antibody against vascular endothelial growth factor A. The tumor volume of the RhoJ-AuNPs + RT (5 Gy) decreased for the first 6 days, and subsequently regressed and reached complete elimination on the 20th day.